NEWS
2026-04-23
ABOUT US
AMS BioteQ (Stock Code: 6864) was founded with a clear mission: to address the global challenge of microbial resistance. Years of dedicated research have built two core technology platforms — PoroVance™ Precision Pore Engineering and Small-Molecule Drug Discovery — which support four parallel product and pipeline axes spanning advanced wound dressings (SIPSIP®), agricultural growing substrates (SeepPlug™), skincare (Lumière d'Art), and a small-molecule drug development pipeline. Combining materials science with molecular engineering, we move research from the laboratory to global markets, delivering better recovery and protection solutions for life.
CORE CONCEPT
Whether it is wound healing, plant rhizospheres, skin microbiomes, or the molecular battle between pathogens and human cells, AMS BioteQ believes the best solutions emerge from a deep understanding of the microenvironment. With our platform-based R&D capabilities, we deliver precision solutions across scenarios, industries, and borders — from molecular innovation in the laboratory to real-world application in clinics and fields.
Dual Platforms × Four Application Axes
Built on these two foundational platforms, AMS BioteQ delivers three commercial product lines — SIPSIP® medical dressings, SeepPlug™ agricultural substrates, and Lumière d'Art skincare — alongside a drug development pipeline including FORMOSA-1117, YUAN-03, AMS-2140, and TenTacle™. One technology core, four life-changing applications.
